Literature DB >> 22103549

Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum.

M S Shareef1, L R Munro, R G Owen, A S Highet.   

Abstract

Pyoderma gangrenosum (PG) may be associated with inflammatory disorders and haematological conditions such as monoclonal gammopathy of uncertain significance (MGUS). We report the case of a 53-year old man who had PG and MGUS. After treatment with infliximab for the PG, he developed myeloma. The course of events in this case suggests that infliximab facilitated the progression from MGUS to myeloma. © The Author(s). CED
© 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22103549     DOI: 10.1111/j.1365-2230.2011.04219.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  4 in total

Review 1.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

2.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

3.  Crohn's disease and smoldering multiple myeloma: a case report and literature review.

Authors:  So Young Park; Jae Min Kim; Hyun Joon Kang; Minje Kim; Jae Joon Han; Chi Hoon Maeng; Sun Kyung Baek; Hwi-Joong Yoon; Si-Young Kim; Hyo Jong Kim
Journal:  Intest Res       Date:  2017-04-27

Review 4.  Cutaneous manifestations of monoclonal gammopathy.

Authors:  Jean-Sebastien Claveau; David A Wetter; Shaji Kumar
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.